2025-07-29
17 分钟At a cabinet meeting earlier this month,
President Trump made an announcement for the pharmaceutical industry.
Like Trump's tariffs on other industries,
A primary goal is to encourage manufacturers to move their operations into the U.S.
And already, some of the largest pharma companies in the world are responding.
But drug makers from one sector of the industry say that manufacturing in the U.S. isn't really an option for them.
I spoke to the CEO of one of those companies.
I'm Richard Sando.
I'm the CEO of a company called Sandoz.
And it is Sandoz or Sanzo?
I feel like I've heard...
People say both.
Yeah.
Sandoz is a Switzerland-based company, and it's one of the world's largest makers of generic drugs.
Generics are medicines whose patents have expired and can be made by many drug companies,
and they generally cost less than brand-name drugs.
Richard has been in talks with the US government,
and he says tariffs aren't the way to encourage companies like his to invest in US manufacturing.
You're working with the Trump administration and having conversations with them,
but you've also spoken publicly about your concerns over these tariffs when it comes to your business,